• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Esperion Theraptc (NQ: ESPR )

    1.990 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.990
    Bid (Size) 1.960 (25)
    Ask (Size) 2.160 (52)
    Prev. Close 1.990
    Today's Range 1.990 - 1.990
    52wk Range 0.7000 - 3.400
    Shares Outstanding 28,277,493
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Esperion to Participate in Upcoming May Investor Conferences
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Report First Quarter 2024 Financial Results on May 7
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    -31.85%
    -31.85%
    1 Month
    -28.67%
    -28.67%
    3 Month
    -8.29%
    -8.29%
    6 Month
    +140.83%
    +140.83%
    1 Year
    +40.14%
    +40.14%

    More News

    Read More
    Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Earnings Scheduled For February 27, 2024
    Via Benzinga
    Why Esperion Therapeutics Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Earnings Preview: Esperion Therapeutics
    Via Benzinga
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    Exposures Glyphosate
    Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Why Is Heart Disease-Focused Esperion Therapeutics Stock Trading Higher On Monday?
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Via InvestorPlace
    Esperion Therapeutics, Masimo And Other Big Stocks Moving Higher In Monday's Pre-Market Session
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
    From Esperion Therapeutics
    Via Business Wire
    U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Esperion to Report Fourth Quarter and Full Year 2023 Financial Results on February 27
    From Esperion Therapeutics, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.